面向连续终点的II期临床试验预测概率期中设计
针对分子靶向治疗试验需同时评估安全性、生物标志物活性或连续肿瘤大小变化而非二分类缓解率的需求,作者提出一种基于预测概率的两阶段设计,假设连续终点服从已知方差的正态分布。模拟与案例研究显示该设计可同时设置无效性与有效性期中停止规则并保持理想设计属性,使用连续肿瘤大小可减少最优设计与极小极大设计的样本量,且对多种先验设置表现稳健。
要点
- 连续终点可用预测概率两阶段设计同时监测无效性与有效性。
- 采用连续肿瘤大小作为终点时最优与极小极大设计的样本量均减少。
- 该设计对多种先验的有限探索显示稳健。
核心结论
- 提出的基于预测概率的两阶段期中设计可容纳连续终点,并能同时设置无效性与有效性期中停止,保持理想的设计属性。
研究设计与样本
- 单臂II期临床试验的两阶段设计方法学研究,基于预测概率,假设连续终点服从已知方差的正态分布,并通过模拟与案例研究进行评估。
主要发现
- 模拟结果与案例研究表明,该设计可同时纳入无效性与有效性期中停止且维持理想设计属性。
- 使用连续肿瘤大小作为终点时,最优设计与极小极大设计的样本量均减少。
- 对多种先验的有限探索显示该设计稳健。
临床怎么用
- 在分子靶向治疗的早期单臂II期试验中,可用连续终点(如肿瘤大小变化)替代二分类缓解率,并借助预测概率设计设置灵活的期中停止规则以优化试验资源。
局限性
- 方法假设连续终点服从正态分布且方差已知;对先验的探索仅为有限范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecular targeted therapies come often with lower toxicity profiles than traditional cytotoxic treatments, thus shifting drug development paradigm into establishing evidence of biological activity, target modulation, and pharmacodynamics effects of these therapies in early phase trials. Therefore, these trials need to address simultaneous evaluation of safety, proof-of-concept biological marker activity, or changes in continuous tumor size instead of binary response rate. Interim analyses are typically incorporated in the trial due to concerns regarding excessive toxicity and ineffective new treatment. There is a lack of interim strategies developed to monitor futility and/or efficacy for these types of continuous outcomes, especially in single-arm phase II trials. We propose a 2-stage design based on predictive probability to accommodate continuous endpoints, assuming a normal distribution with known variance. Simulation results and case study demonstrated that the proposed design can incorporate an interim stop for futility as well as for efficacy while maintaining desirable design properties. As expected, using continuous tumor size resulted in reduced sample sizes for both optimal and minimax designs. A limited exploration of various priors was performed and shown to be robust. As research rapidly moves to incorporate more molecular targeted therapies, it will accommodate new types of outcomes while allowing for flexible stopping rules to continue optimizing trial resources and prioritize agents with compelling early phase data.
引用
- Liu M, Dressler EV. A predictive probability interim design for phase II clinical trials with continuous endpoints. Stat Med. 2018. PMID: 29611211. doi:10.1002/sim.7659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。